title: Measles-mumps-rubella immunization of susceptible hospital employees during a community measles outbreak: cost-effectiveness and protective efficacy.
abstract: OBJECTIVE
  To determine cost-effectiveness and protective efficacy of a program to identify and immunize susceptible hospital employees during a measles outbreak.
  
  
  METHODS
  A cost analysis was made of blind measles-mumps-rubella (MMR) immunization versus directed MMR immunization based on 2,000 employees born after December 31, 1956. A directed MMR immunization program for susceptible employees was instituted. Actual costs of the program were calculated at the conclusion of the program.
  
  
  METHODS
  A medical center complex with more than 4,000 employees, two acute care community hospitals, and a tertiary care children's hospital.
  
  
  RESULTS
  A directed MMR immunization program was projected to be less expensive than blind immunization ($23,106 versus $70,720). MMR vaccine was administered to 169 of 188 susceptible employees. Actual cost of the directed MMR immunization program was $25,384.
  
  
  CONCLUSIONS
  The directed MMR immunization program was cost-effective and prevented secondary cases among hospital employees during a community measles outbreak.
authors.affiliation: Kosair Children's Hospital, Louisville, KY 40232.
authors.forename: B H
authors.initials: BH
authors.lastname: Stover
authors.forename: G
authors.initials: G
authors.lastname: Adams
authors.forename: C A
authors.initials: CA
authors.lastname: Kuebler
authors.forename: K M
authors.initials: KM
authors.lastname: Cost
authors.forename: G P
authors.initials: GP
authors.lastname: Rabalais
mesh_terms: D017714:Community-Acquired Infections / Q000097:blood / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D004196:Disease Outbreaks / Q000191:economics; D004338:Drug Combinations; D006801:Humans; D017053:Infection Control / Q000458:organization & administration*; D007629:Kentucky / Q000453:epidemiology; D008403:Mass Screening / Q000458:organization & administration*; D008457:Measles / Q000097:blood / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D008458:Measles Vaccine / Q000191:economics*; D022542:Measles-Mumps-Rubella Vaccine; D009096:Multi-Institutional Systems; D009108:Mumps Vaccine / Q000191:economics*; D009786:Occupational Health Services / Q000191:economics / Q000458:organization & administration*; D010564:Personnel, Hospital; D015397:Program Evaluation; D012411:Rubella Vaccine / Q000191:economics*
chemical_list: D004338:Drug Combinations; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine